Ruxolitinib is a medication indicated for the treatment of certain serious conditions, specifically myelofibrosis, polycythemia vera, and acute graft-versus-host disease (GVHD) in patients who have not responded well to other therapies. It works by targeting and inhibiting certain enzymes involved in cell growth, thereby helping to manage abnormal cell production and reduce symptoms associated with these diseases.
Treatment Of Disease-related Splenomegaly Or Symptoms In Patients With Primary Myelofibrosis, Postpolycythaemia Veramyelofibrosis, Or Post-essential Thrombocythaemia Myelofibrosis:
Adults: Platelets Count 50000-100000/mm3: 5 Mg Twice Daily; 100000-200000/mm3: 15 Mg Twice Daily; >200000/ Mm3: 20 Mg Twice Daily. Increase According To Response And Blood Counts; Starting Dose May Be Increased After 4 Wk By Max 5 Mg Twice Daily At > 2 Wk Intervals. Max Dose 25 Mgtwice Daily. Discontinue If No Response After 6 Mth, Or If 40% Increase In Baseline Spleen Length Without Sustained Symptom Improvement.
